Corbus craters on ‘surprising’ late-stage lenabasum flop

Corbus pharmaceuticals saw its shares fall more than 75% after its phase 3 trial of lenabasum in cutaneous systemic sclerosis patients failed to beat out placebo.

The topline data, with a more detailed look to come, showed no significant differences in both the primary and secondary endpoints when comparing FDA fast-tracked lenabasum to a dummy treatment, both of which were added to background, typically immunosuppressive drug therapy.